[ET Net News Agency, 25 May 2021] Goldman Sachs raised its target price for CSPC Pharma
(01093) to HK$13.5 from HK$12.5.
The research house said key downside risks are (1) slower NBP and oncology revenue
growth; (2) failure of major R&D projects; and (3) slow progress in BD. (RC)